Sugi Predict

Sugi Predict / Compounds / SCHEMBL4598588

SCHEMBL4598588

SCHEMBL4598588

COCCCOc1ccc(Br)cc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DRD4 P21917 2/20 0.53
▸ DRD2 P14416 1/20 0.53
▸ DRD3 P35462 1/20 0.53
▸ KDM4E B2RXH2 3/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ ATM Q13315 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ RECQL P46063 2/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ MAPT P10636 1/20 0.45
▸ TSHR P16473 1/20 0.44
▸ NOS1 P29475 2/20 0.44
▸ CHRNA7 P36544 1/20 0.44
▸ MAOB P27338 2/20 0.43
▸ LTA4H P09960 1/20 0.43
▸ PTGS2 P35354 1/20 0.43
▸ RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4598755 0.96 DRD4 (0.53) DRD4DRD2DRD3KDM4EALDH1A1
SCHEMBL6133006 0.94 DRD4 (0.51) DRD4DRD2DRD3KDM4EALDH1A1
SCHEMBL6132842 0.94 DRD4 (0.51) DRD4DRD2DRD3KDM4EALDH1A1
SCHEMBL410729 0.89 KDM4E (0.52) DRD4DRD2DRD3KDM4EALDH1A1
SCHEMBL18235025 0.89 DRD4 (0.57) DRD4DRD2DRD3KDM4EALDH1A1
SCHEMBL7333293 0.88 DRD4 (0.47) DRD4DRD2DRD3KDM4EALDH1A1
SCHEMBL7317588 0.88 DRD4 (0.47) DRD4DRD2DRD3KDM4EALDH1A1
SCHEMBL7339801 0.88 DRD4 (0.47) DRD4DRD2DRD3KDM4EALDH1A1
SCHEMBL7334037 0.88 DRD4 (0.47) DRD4DRD2DRD3KDM4EALDH1A1
SCHEMBL20662545 0.87 KDM4E (0.49) DRD4DRD2DRD3KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2025-01-23 — — US disclosed
US-12060349-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2024-08-13 — — US disclosed
EP-4098654-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS Genzyme Corporation (US) 2022-12-07 — — EP disclosed
CN-114533729-A Glucosylceramide synthase inhibitors 建新公司 2022-05-27 — — CN disclosed
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2022-03-10 — — US disclosed
EP-2895484-B1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORP (US) 2022-02-23 — — EP disclosed
CN-108864076-B Glucosylceramide synthase inhibitors 建新公司 2022-02-11 — — CN disclosed
US-11071736-B2 Modulators of HEC1 activity and methods therefor TAIVEX THERAPEUTICS CORPORATION 2021-07-27 — — US disclosed
US-11008316-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2021-05-18 — — US disclosed
US-10588909-B2 Modulators of HEC1 activity and methods therefor TAIVEX THERAPEUTICS CORPORATION (TW) 2020-03-17 — — US disclosed
WO-2014043068-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2014-03-20 — — WO disclosed
CN-102351734-B Preparation method for aliskiren ZHEJIANG APELOA PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD 2014-02-26 — — CN disclosed
US-20130190312-A1 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR TAIVEX THERAPEUTICS CORPORATION (TW) 2013-07-25 — — US disclosed
US-20130190312-A1 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR TAIVEX THERAPEUTICS CORPORATION (TW) 2013-07-25 — — US disclosed
WO-2013082324-A1 IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR TAIVEX THERAPEUTICS CORPORATION (TW) 2013-06-06 — — WO disclosed
WO-2013082324-A1 IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR TAIVEX THERAPEUTICS CORPORATION (TW) 2013-06-06 — — WO disclosed
EP-1908471-A1 Tetrahydropyridines as renin inhibitors Speedel Experimenta AG (CH) 2008-04-09 — — EP disclosed
EP-1140896-A1 BENZOTHIEPIN-ANILIDE DERIVATIVES, THEIR PRODUCTION AND THEIR USE FOR ANTAGONIZING CCR-5 Takeda Chemical Industries, Ltd. (JP) 2001-10-10 — — EP disclosed
US-6235771-B1 AIDS THERPAY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-05-22 — — US disclosed
WO-2000037455-A1 BENZOTHIEPIN-ANILIDE DERIVATIVES, THEIR PRODUCTION AND THEIR USE FOR ANTAGONIZING CCR-5 TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2000-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190312-A1 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR WEE1, WEE2, NEK11 DRD4 4732/4885DRD2 4377/4885DRD3 4547/4885
US-11008316-B2 Glucosylceramide synthase inhibitors GBA1, GBA2, GAA DRD4 4875/4885DRD2 4845/4885DRD3 4850/4885
US-12060349-B2 Glucosylceramide synthase inhibitors GBA1, GBA2, GALC DRD4 4873/4885DRD2 4849/4885DRD3 4839/4885
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA DRD4 4878/4885DRD2 4837/4885DRD3 4821/4885
US-10588909-B2 Modulators of HEC1 activity and methods therefor WEE1, WEE2, NEK11 DRD4 4732/4885DRD2 4377/4885DRD3 4547/4885
US-11071736-B2 Modulators of HEC1 activity and methods therefor WEE1, WEE2, NEK11 DRD4 4732/4885DRD2 4377/4885DRD3 4547/4885
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA DRD4 4878/4885DRD2 4837/4885DRD3 4821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.